BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Drusano G, Lode H, Edwards J. Meropenem: clinical response in relation to in vitro susceptibility. Clinical Microbiology and Infection 2000;6:185-94. [DOI: 10.1046/j.1469-0691.2000.00062.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 14] [Article Influence: 0.4] [Reference Citation Analysis]
Number Citing Articles
1 Akhi MT, Asghari B, Nahaei MR, Memar MY, Lari AR, Naghili B, Pirzadeh T. Comparison of in vitro activities of meropenem productions on Klebsiella pneumoniae isolated from hospitalized patients. GMS Hyg Infect Control 2014;9:Doc12. [PMID: 25152857 DOI: 10.3205/dgkh000232] [Reference Citation Analysis]
2 Petrella S, Ziental-Gelus N, Mayer C, Renard M, Jarlier V, Sougakoff W. Genetic and structural insights into the dissemination potential of the extremely broad-spectrum class A beta-lactamase KPC-2 identified in an Escherichia coli strain and an Enterobacter cloacae strain isolated from the same patient in France. Antimicrob Agents Chemother 2008;52:3725-36. [PMID: 18625772 DOI: 10.1128/AAC.00163-08] [Cited by in Crossref: 64] [Cited by in F6Publishing: 41] [Article Influence: 4.6] [Reference Citation Analysis]
3 Giske CG, Borén C, Wretlind B, Kronvall G. Meropenem susceptibility breakpoint for Pseudomonas aeruginosa strains hyperproducing mexB mRNA. Clin Microbiol Infect 2005;11:662-9. [PMID: 16008620 DOI: 10.1111/j.1469-0691.2005.01182.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
4 Griffith DC, Sabet M, Tarazi Z, Lomovskaya O, Dudley MN. Pharmacokinetics/Pharmacodynamics of Vaborbactam, a Novel Beta-Lactamase Inhibitor, in Combination with Meropenem. Antimicrob Agents Chemother 2019;63:e01659-18. [PMID: 30397063 DOI: 10.1128/AAC.01659-18] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 5.8] [Reference Citation Analysis]
5 Su TY, Ye JJ, Yang CC, Huang CT, Chia JH, Lee MH. Influence of borderline cefepime MIC on the outcome of cefepime-susceptible Pseudomonas aeruginosa bacteremia treated with a maximal cefepime dose: a hospital-based retrospective study. Ann Clin Microbiol Antimicrob 2017;16:52. [PMID: 28738848 DOI: 10.1186/s12941-017-0227-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
6 McLaughlin MM, Miglis C, Skoglund E, Wagner J, Advincula MR, Scheetz MH. Effect of elevated imipenem/cilastatin minimum inhibitory concentrations on patient outcomes in Gram-negative bloodstream infections. J Glob Antimicrob Resist 2018;13:261-3. [PMID: 29432939 DOI: 10.1016/j.jgar.2018.02.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
7 Lowe MN, Lamb HM. Meropenem: an updated review of its use in the management of intra-abdominal infections. Drugs 2000;60:619-46. [PMID: 11030471 DOI: 10.2165/00003495-200060030-00010] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 1.0] [Reference Citation Analysis]
8 Torres E, Delgado M, Valiente A, Pascual Á, Rodríguez-baño J. Impact of borderline minimum inhibitory concentration on the outcome of invasive infections caused by Enterobacteriaceae treated with β-lactams: a systematic review and meta-analysis. Eur J Clin Microbiol Infect Dis 2015;34:1751-8. [DOI: 10.1007/s10096-015-2408-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
9 Unal S, Garcia-Rodriguez JA. Activity of meropenem and comparators against Pseudomonas aeruginosa and Acinetobacter spp. isolated in the MYSTIC Program, 2002-2004. Diagn Microbiol Infect Dis 2005;53:265-71. [PMID: 16360550 DOI: 10.1016/j.diagmicrobio.2005.10.002] [Cited by in Crossref: 50] [Cited by in F6Publishing: 38] [Article Influence: 3.1] [Reference Citation Analysis]
10 Jones RN, Mendes C, Turner PJ, Masterton R. An overview of the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Program: 1997-2004. Diagn Microbiol Infect Dis 2005;53:247-56. [PMID: 16360548 DOI: 10.1016/j.diagmicrobio.2005.10.006] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 2.0] [Reference Citation Analysis]
11 Cielecka-piontek J, Szymanowska-powałowska D, Paczkowska M, Łysakowski P, Zalewski P, Garbacki P. Stability, compatibility and microbiological activity studies of meropenem–clavulanate potassium. J Antibiot 2015;68:35-9. [DOI: 10.1038/ja.2014.92] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
12 Falagas ME, Tansarli GS, Rafailidis PI, Kapaskelis A, Vardakas KZ. Impact of antibiotic MIC on infection outcome in patients with susceptible Gram-negative bacteria: a systematic review and meta-analysis. Antimicrob Agents Chemother 2012;56:4214-22. [PMID: 22615292 DOI: 10.1128/AAC.00663-12] [Cited by in Crossref: 49] [Cited by in F6Publishing: 20] [Article Influence: 4.9] [Reference Citation Analysis]
13 Binder L, Schwörer H, Hoppe S, Streit F, Neumann S, Beckmann A, Wachter R, Oellerich M, Walson PD. Pharmacokinetics of meropenem in critically ill patients with severe infections. Ther Drug Monit. 2013;35:63-70. [PMID: 23318279 DOI: 10.1097/ftd.0b013e31827d496c] [Cited by in Crossref: 31] [Cited by in F6Publishing: 13] [Article Influence: 3.4] [Reference Citation Analysis]
14 Maglio D, Teng R, Thyrum PT, Nightingale CH, Nicolau DP. Pharmacokinetic profile of meropenem, administered at 500 milligrams every 8 hours, in plasma and cantharidin-induced skin blister fluid. Antimicrob Agents Chemother 2003;47:1771-3. [PMID: 12709358 DOI: 10.1128/AAC.47.5.1771-1773.2003] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
15 Alba J, Ishii Y, Thomson K, Moland ES, Yamaguchi K. Kinetics study of KPC-3, a plasmid-encoded class A carbapenem-hydrolyzing beta-lactamase. Antimicrob Agents Chemother 2005;49:4760-2. [PMID: 16251324 DOI: 10.1128/AAC.49.11.4760-4762.2005] [Cited by in Crossref: 52] [Cited by in F6Publishing: 30] [Article Influence: 3.3] [Reference Citation Analysis]